CFDE Data Portal | Search RN7SL440P

	Label	Description
	RN7SL440P Gene (Entity type)	ENSG00000264963 - RNA, 7SL, cytoplasmic 440, pseudogene
	GSE225375 CDK12 CDK13 inhibition 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 4 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE209698 calcitriol D 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 progesterone fibroblast 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE139540 menadione 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 11 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 4 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE139540 menadione 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE165548 gemcitabine 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS

RN7SL440P

ENSG00000264963 - RNA, 7SL, cytoplasmic 440, pseudogene

GSE225375 CDK12 CDK13 inhibition 2 v 0 human up

A Gene Set from LINCS

GSE100148 EZH2 inhibition 4 v 5 human dn

A Gene Set from LINCS

GSE209698 calcitriol D 2 v 1 human up

A Gene Set from LINCS

GSE220806 progesterone fibroblast 0 v 3 human up

A Gene Set from LINCS

GSE139540 menadione 0 v 1 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 11 v 5 human dn

A Gene Set from LINCS

GSE100148 EZH2 inhibition 4 v 7 human dn

A Gene Set from LINCS

GSE139540 menadione 4 v 1 human dn

A Gene Set from LINCS

GSE165548 gemcitabine 2 v 4 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.